Lilly's (LLY.US) three-year study of Tirzepatide shows sustained benefits for weight loss, diabetes

Market IntelThursday, Nov 14, 2024 1:40 am ET

1min read

More detailed results from the third phase of clinical study SURMOUNT-1 from Eli Lilly (LLY.US) showed that the active ingredient tirzepatide in its obesity drug Wegovy and type 2 diabetes drug Ozempic can bring sustainable weight loss and diabetes benefits.

Three years later, people taking 15mg (the highest dose tested) had an average weight loss of 22.9%.

Tirzepatide was associated with a 94% reduction in the risk of diabetes progression compared to the placebo group in all three doses tested.

About 1,000 patients participating in the trial, who were considered obese or overweight, were in the pre-diabetes stage and were randomly assigned to one of three doses or the placebo group.

Eli Lilly noted that 99% of patients taking tirzepatide did not develop diabetes within three years.

The results of SURMOUNT-1 today were based on the results published in August.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.